Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Core Insights - Werewolf Therapeutics, Inc. reported a quarterly loss of $0.43 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.38, and a significant increase from a loss of $0.14 per share a year ago [1] - The company posted revenues of $1.14 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 42.85% and down from $8.08 million in the same quarter last year [2] - The stock has underperformed significantly, losing about 55.7% since the beginning of the year compared to the S&P 500's gain of 9% [3] Financial Performance - The earnings surprise for the recent quarter was -13.16%, and the company has not been able to beat consensus revenue estimates over the last four quarters [1][2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $2 million, and for the current fiscal year, it is -$1.52 on revenues of $6.85 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Werewolf Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a relatively strong position [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Werewolf Therapeutics' stock performance [5]